Enliven Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview

Enliven Therapeutics

02/05/2023 19:33

* Enliven Therapeutics Inc  ELVN.OQ   ELVN.O  is expected
to show
no change in quarterly revenue when it reports  results on May 4
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Enliven
Therapeutics Inc
is for a loss of 63 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "Buy".​
    * Wall Street's median 12-month price target for Enliven
Therapeutics Inc is $32​, above​ its last closing price
of $19.30. ​​​

This summary was machine generated May 2 at 18:33 GMT.  All
figures in US dollars  unless otherwise stated